Review
Nature Reviews Drug Discovery 1, 493-502 (July 2002) | doi:10.1038/nrd839
Article series: Case Histories
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Renaud Capdeville1, Elisabeth Buchdunger1, Juerg Zimmermann1 & Alex Matter1 About the authors
Abstract
In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.
- View At a Glance
Author affiliations
- Novartis Oncology, Novartis Pharma AG, S-27 2.033, CH-4002 Basel, Switzerland.
Correspondence to: Renaud Capdeville1 Email: renaud.capdeville@pharma.novartis.com
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE NEWS AND VIEWS RESEARCH |
receptor: a new clinical target for STI571/Glivec
